CliffBio
small molecule

AKTEN

LIDOCAINE HYDROCHLORIDE

Loss of exclusivityJuly 2026latest FDA-listed patent expiry
CompanyThea →See this company's full patent-cliff portfolio

Drug detail

Brand nameAKTEN
Active ingredientLIDOCAINE HYDROCHLORIDE
Strength3.5%
Dosage formGEL
RouteOPHTHALMIC
ModalitySmall molecule
FDA approvalOctober 2008
Marketing statusRX

Listed patents

PatentExpiresType
8759401July 2026product

More from Thea

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

AKTEN patent cliff — loss of exclusivity July 2026 | CliffBio